Prevencio launched its third test, HART PAD, for diagnosis of peripheral artery disease in U.S. adults.
Published
Signal category
Products & Services
Quote
“Proud to be on our dedicated Prevencio team launching our 3rd test, HART PAD, for diagnosis of peripheral artery disease (PAD) in U.S. adults.”
— Rhonda F. Rhyne|Prevencio team
Company
Prevencio
Power of AI to Prevent the Preventable
- Location
- KIRKLAND, US
- Company size
- 12 employees
Prevencio is Revolutionizing Blood Tests For Cardiovascular Disease || Powered by Artificial Intelligence (AI) || Preventative Medicine for Heart Health Prevencio's purpose is to prevent the preventable. 80% of cardiovascular disease, including heart disease and stroke, are preventable (CDC). Prevencio's personalized blood tests provide earlier detection and prevention which can diminish unnecessary procedures and related side effects, as well as improve patient outcomes. Published in top-tier cardiology journals and presented at leading cardiovascular meetings, Prevencio's patented, proprietary technology has been used to create seven life-saving cardiovascular tests, with more in development. Prevencio utilizes Machine Learning (Artificial Intelligence) + Multi-Proteomic Biomarkers + Proprietary Algorithms to deliver cardiovascular diagnostic & prognostic tests that are significantly more accurate than standard-of-care stress tests, individual biomarkers, genetic markers and clinical risk scores. To learn more visit us at: www.prevenciomed.com